anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Currently the patient is defined as an older adult (OA) when the age is at least 60 years. Given the long life expectancy, it is interesting to evaluate whether all OAs with acute myocardial infarction (AMI) are equal. The objectives were to know the prevalence of OA in AMI and within them, that of those ≥75 years of age and to analyze characteristics, reperfusion treatments and in-hospital mortality according to whether they are < or ≥ 75 years of age.
METHODS: OA patients admitted to the National Registry of Infarction with ST segment elevation (ARGENIAM-ST) were analyzed. They were divided into group 1: 60-74 years old and group 2: ≥ 75 years old and compared with each other.
RESULTS: 3626 AM, 75.9% from Group 1, the rest from Group 2. In group 2 there were more women, hypertensive and with a history of coronary arteries. There was a similar percentage of diabetes and dyslipidemia, but fewer of smokers. In Group 2, less reperfusion treatment was used (although more primary angioplasty), with similar door-to-balloon time. Patients in Group 2 received fewer medications of proven efficacy and in the hospital course, they had more bleeding (although not major), more heart failure and more mortality: 18.3% vs. 9.4%, p<0.001. Age ≥75 years was an independent predictor of mortality.
CONCLUSIONS: one in four patients with AMI is over 75 years old; they receive less reperfusion, have more heart failure, bleeding and twice the mortality rate than patients between 60 and 74 years.
A system for providing intrabody communication using acoustic telemetry. The system includes a first or control implant including a first acoustic transducer, and a second implant including a switch and a second acoustic transducer coupled to the switch. The second acoustic transducer receives acoustic signals from the first acoustic transducer for closing the switch to activate the second implant. The second implant may include a sensor for measuring a physiological parameter that is transmitted using acoustic signals including the physiological data to the first implant. For example, the second implant may measure pressure in the patient's heart that may be used by the first implant to control a pacemaker. Alternatively, the second implant may blood sugar concentration that may be used by the first implant to control an insulin pump. Alternatively, the first implant may store and transfer the data to an external device for monitoring the patient.
INTRODUCTION: Cerebral ischemia (CI) induces a profound neuroinflammatory response, but the underlying molecular mechanism remains unclear. Exosomes from adipose-derived stem cells (ADSC-exos) have been found to play a crucial role in cell communication by transferring molecules including microRNAs (miRNAs), which have been shown to modulate the inflammatory response after CI and are viable molecular targets for altering brain function. The current study aimed to explore the contribution of ADSC-exosomal miR-21-5p to the neuroinflammation after CI.
METHODS: The differentially expressed miR-21-5p in CI was screened based on literature search. The target mRNAs of miR-21-5p were predicted using online databases and verified by luciferase reporter assay. Then, BV2 cells were treated with hemin to simulate the inflammatory response after CI, and its animal model was induced using the MCAO method. Ischemia was evaluated in rats using 2, 3, 5-triphenyl tetrazolium chloride (TTC) staining. ADSCs-exos were further isolated and identified by western blot analysis and transmission electron microscope.
RESULTS: MiR-21-5p was significantly down-regulated in CI and alleviated neuropathic damage after CI by the PIK3R1/PI3K/AKT signaling axis. And miR-21-5p derived from ADSCs-exos alleviated neuroinflammation after CI via promoting microglial M2 polarization.
CONCLUSION: We demonstrated that ADSC-exosomal miR-21-5p mitigated post-CI inflammatory response through the PIK3R1/PI3K/AKT signaling axis and could offer neuroprotection after CI through promoting polarization of M2 microglia.
OBJECTIVES: This study aimed to assess the mortality and prognosis of acute myocardial infarction (AMI) patients with out-of-hospital cardiac arrest (OHCA) initially admitted to Department of Anesthesiology and Intensive Care in comparison with patients initially admitted to Cardiac Centre (CC).
BACKGROUND: Global acute coronary syndrome (ACS) registries often omit patients with OHCA initially admitted to anaesthesiology and intensive care units. This exclusion may lead to underestimated mortality rates in patients following acute MI worldwide.
METHODS: A retrospective analysis was conducted in patients admitted in 2014 to the (Department of Anesthesiology and Intensive Care) at a single center, J.A. Reiman Teaching Hospital in Presov, Slovakia. Survival rates were evaluated in-hospital, at 30 days, and annually over a five-year period. Patients with STEMI and NSTEMI were analyzed separately, particularly during the early in-hospital phase.
RESULTS: In the OHCA group, 52% of STEMI patients experienced in-hospital mortality, whereas the CC group reported only 3% mortality. The total hospital mortality for STEMI patients was 6.69%. Among NSTEMI patients in the OHCA group, in-hospital mortality reached 50%, compared to 4.33% in the CC group. The total center mortality for all NSTEMI patients was 6.09%.
CONCLUSION: Although the short-term prognosis for MI patients with OHCA is unfavorable, with a 30-day mortality rate of 54.9%, for those who survive the initial 30 days following cardiac arrest and are successfully discharged from the hospital, the long-term prognosis aligns with MI patients without OHCA. In light of these findings, the inclusion of all patients with MI (from both OHCA and CC groups) in global ACS registries could significantly raise in-hospital and 30-day mortality rates (Tab. 3, Fig. 4, Ref. 21).
For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. On Day 8, PTK 787 250 mg by mouth every day and imatinib 600 mg by mouth every day (for Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia- blastic phase (CML-BP) and imatinib 400 mg by mouth every day (for Agnogenic Myeloid Metaplasia (AMM). Length of therapy is four courses; each course equals 28 days. Patients assessed for response after each course.
OBJECTIVE: Surgical indications for low-grade carotid stenosis have not yet been established. This study aimed to clarify the characteristics of low-grade carotid stenosis refractory to medical treatment.
METHODS: We retrospectively analyzed 48 patients with symptomatic low-grade carotid stenosis (<50%). Recurrence was defined as an ipsilateral ischemic event in the symptomatic lesions during the follow-up period. Patient demographics and imaging findings were compared between the recurrence and nonrecurrence groups to investigate risk factors associated with medical treatment.
RESULTS: The mean age was 74.1 (58-90 years), and the mean follow-up period was 35.4 months (2.0-97 months). Recurrence occurred in 15 of the symptomatic patients. Ulceration was significantly associated with recurrence under medical treatment (P = 0.001). The median time to recurrence was 26.1 months in patients with ulcers and 54.3 months in those without ulcers (P = 0.04). Pathological study with recurrence showed plaque rupture with multilayered lesions, indicating lesions refractory to medical treatment.
CONCLUSIONS: In cases of low-grade carotid stenosis, lesions with ulcerations are likely refractory to medical therapy. Consideration of the indications for surgical treatment may be warranted for lesions with ulceration, even if the degree of stenosis is low.
A single use capsule containing dentifrice is disclosed. It includes toothpaste or other dentifrice enclosed in a shell or coating. The dentifrice may include miswak fibers, which acts as a natural brush, therefore obviating the need for a traditional brush. The coating may include choline and albumin. In use, a capsule is placed in the mouth, burst with the teeth, and then distributed throughout the mouth with the tongue. The teeth can then be brushed with a traditional brush, or the tongue can rub the miswak fibers over the teeth in lieu of using a brush.
<P>PROBLEM TO BE SOLVED: To provide a gargle exhibiting high germicidal effects and anti-inflammatory effects, having rapid effects and hardly staining clothes or the like.  <P>SOLUTION: The gargle includes an aqueous solution of zinc chloride as a main component. The concentration of the aqueous solution of the zinc chloride is regulated so as to be 0.40-0.01%. The zinc chloride of guaranteed reagent is used, and distilled water or purified water is used as the water of a solvent. Preferably, an astringent drug such as borax, boric acid and alum of 0.40-0.00001 wt.% is mixed therewith. Optionally, a perfume such as L-menthol, peppermint oil and rose oil of 1.0-0.00001 wt.% is mixed therewith. An antiseptic agent or a coloring agent can be added thereto.  <P>COPYRIGHT: (C)2009,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide a method for producing an antimicrobial extract having excellent antimicrobial properties, the antimicrobial extract obtained by the method and an antimicrobial agent composition comprising the antimicrobial extract.  <P>SOLUTION: The method for producing the antimicrobial extract is carried out as follows. A plant containing an antimicrobial ingredient such as Acer cissifolium or Magnolia grandiflora as a raw material is crushed until a powdery form is obtained. The resultant powder is then subjected to a pressurizing steam extraction treatment under conditions of 121°C and 2 atm for 20 min. The antimicrobial extract obtained by the method for producing the antimicrobial extract exhibits the antimicrobial properties for both Staphylococcus aureus which is a Gram-positive bacterium and Escherichia coli that is a Gram-negative bacterium. Thereby, the antimicrobial extract has a wide antimicrobial spectrum and the excellent antimicrobial properties.  <P>COPYRIGHT: (C)2004,JPO
Determining whether a patient is eligible to receive benefits under a healthcare assistance program. Initial patient information, such as the patient's date of birth, the members of the patient's household, the patient's medical condition, including pregnancy, and the patient's income and financial resources, if available, is used to make an initial determination as to whether the patient is likely to qualify for benefits. The initial patient information is compared to a set of well-established criteria and probability models. The well-established criteria are based on judicial or agency eligibility determinations. The probability models are based on past experience in obtaining benefits for patients. If the initial patient information satisfies one of the well-established criteria or the probability models, then additional patient information is obtained. The additional patient information typically includes additional details about the patient's income and financial resources, as well as the income and financial resources of the other members of the patient's household. The patient information is compared to the eligibility requirements for the assistance program. If the comparison indicates that it is likely that the patient will qualify for benefits under the assistance program, then an application for the assistance program is provided and the application is completed and submitted.
OBJECTIVES: I. Determine the response rate and failure-free survival in patients with metastatic cancer (preferably melanoma or renal cell) treated with autologous tumor infiltrating lymphocytes (TIL), interferon alfa (IFN-A), and interleukin-2 (IL-2). II. Describe the toxic effects and costs associated with this therapy to assess risk benefit and cost benefit. III. Assess the relative value of administering low- or high-dose TIL, as well as the value of administering IFN-A before TIL, IL-2 with TIL, or cimetidine with TIL.

OUTLINE: This is a multicenter study. Patients are stratified according to center, tumor infiltrating lymphocyte (TIL) dose (low vs high), and medical condition suitable for interferon alfa (IFN-A)/interleukin-2 (IL-2) (yes vs no). Patients are assigned to one of two treatment regimens based on entry criteria. Regimen A (preferred): Patients meeting the preferred entry criteria receive IFN-A subcutaneously on days 1-4, TIL expanded in vitro with IL-2 IV on day 5, and IL-2 IV continuously over 72 hours following TIL infusion. Regimen B: All other patients receive TIL infusion once followed by oral cimetidine every 6 hours for 4 weeks. Treatment repeats in both regimens every 3-6 weeks in the absence of disease progression and according to TIL availability. Patients are followed every 6 months.

PROJECTED ACCRUAL: A total of 20-30 patients with melanoma and 20-30 patients with renal cell carcinoma will be accrued for this study.
Systems and methods for a multi-platform prescription routing system in a network are provided. The system includes a network interface communicatively coupled to a computer network, the network interface including a receiver and a transmitter. The system includes at least one processor communicatively coupled to the network interface. The processor is configured to transmit the first prescription to the first supplier, and the second prescription to the second supplier for fulfillment. The processor is further configured to receive, via the network interface, status updates from the one or more suppliers. The processor is further configured to transmit, via the network interface, the status updates to the at least one user device in a format through which the status updates from the first supplier and the second supplier are together viewable by the patient within a single user interface at the user device.
INTRODUCTION: Oral squamous cell carcinoma is a major cause of death throughout the developed world. Human papillomavirus (HPV) type 16 has also been suggested to play a role in etiology of head and neck squamous cell carcinoma (HNSCC). p16 expression is now being used as a surrogate marker of HPV infection in squamous cell carcinoma. Dysfunction in the p53 tumor suppressor gene is implicated in many cancers, including head and neck cancer. Overexpression or mutation of EGFR is found in 80%-100% of the patients with HNSCC, and is associated with poor prognosis and decreased survival.
MATERIALS AND METHODS: In this cross-sectional observation study, total of 100 cases of HNSCC were taken. p16, p53, and EGFR expression was determined by immunohistochemical staining and correlated with clinicopathological parameters. p16 expression was also correlated with expression of p53 and EGFR. The obtained results were analyzed and evaluated using Chi-square test, value of P < 0.05 was taken significant.
RESULTS: p16, p53, and EGFR were positive in 60%, 44%, and 58% cases, respectively. A statistically significant association was observed between p16 with age, site of the tumor, abnormal sexual habits and lymph node involvement. Significant expression also seen between p53 with age and abnormal sexual habits and immunohistochemical expression of p16 with p53 and EGFR.
CONCLUSION: Immunohistochemical expression of p16 can be used as a surrogate marker of HPV. Study of p16, p53, and EGFR expression may provide clinicians with more exact information in order to evaluate tumor aggressiveness and treatment modalities.
Food is Medicine (FIM) programs to improve the accessibility of fruits and vegetables (FVs) or other healthy foods among patients with low income and diet-related chronic diseases are promising to improve food and nutrition security in the United States (US). However, FIM programs are relatively new and implementation guidance for healthcare settings using an implementation science lens is lacking. We used a narrative review to describe the evidence base on barriers and facilitators to FIM program integration in US healthcare settings following the Exploration, Preparation, Implementation, and Sustainment (EPIS) Framework. Evidence surrounding the EPIS Inner Context was a focus, including constructs Leadership, Organizational Characteristics, Quality and Fidelity Monitoring and Support, Organizational Staffing Processes, and Individual Characteristics. Peer-reviewed and grey literature about barriers and facilitators to FIM programs were of interest, defined as programs that screen and refer eligible patients with diet-related chronic disease experiencing food insecurity to healthy, unprepared foods. Thirty-one sources were included in the narrative review, including 22 peer-reviewed articles, four reports, four toolkits, and one thesis. Twenty-eight sources (90%) described EPIS Inner Context facilitators and 26 sources (84%) described FIM program barriers. The most common barriers and facilitators to FIM programs were regarding Quality and Fidelity Monitoring and Support (e.g., use of electronic medical records for tracking and evaluation, strategies to support implementation) and Organizational Staffing Processes (e.g., clear delineation of staff roles and capacity); although, barriers and facilitators to FIM programs were identified among all EPIS Inner Context constructs. We synthesized barriers and facilitators to create an EPIS-informed implementation checklist for healthcare settings for use among healthcare organizations/providers, partner organizations, and technical assistance personnel. We discuss future directions to align FIM efforts with implementation science terminology and theories, models, and frameworks to improve the implementation evidence base and support FIM researchers and practitioners.
Myasthenia gravis (MG) is a rare autoantibody-mediated disease affecting the neuromuscular junction. We performed a genome-wide association study of 5708 MG cases and 432,028 controls of European ancestry and a replication study in 3989 cases and 226,643 controls provided by 23andMe Inc. We identified 12 independent genome-wide significant hits (P < 5e-8) across 11 loci. Subgroup analyses revealed two of these were associated with early-onset (at age <50) and four with late-onset MG (at age ≥ 50). Imputation of human leukocyte antigen alleles revealed inverse effect sizes for late- and early-onset, suggesting a potential modulatory influence on the time of disease manifestation. We assessed the performance of polygenic risk scores for MG, which significantly predicted disease status in an independent target cohort, explaining 4.21% of the phenotypic variation (P = 5.12e-9). With this work, we aim to enhance our understanding of the genetic architecture of MG.
Oral probiotic supplementation (Pro-Probiotic) was provided by iHealth; Cromwell, USA. Each sachet included a 1×1010 CFUs dose of four viable microbial cell preparation strains: there are two strains of lactobacillus genus (Lactobacillus acidophillus L1 (2.9×109) and Lactobacillus rhamnosus liobif (2.9×109)), Bifidobacterium longum (2.9×109) and Saccharomyces boulardii (1.3×109). Each participant took a total daily dose of 4×1010 CFUs.
Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels, positive gadolinium late enhancement and/or positive myocardial infarction suffer from chronic myocardial infarction or significant coronary stenosis. They will be allocated to group 2 and receive coronary angiography in a timely manner according to clinical routine and current guidelines.
BACKGROUND: The use of self-analgesics among women for dysmenorrhoea is common. Non-pharmacological methods can be employed to effectively cope with dysmenorrhoea. Psychoeducation based on Leventhal's Self-Regulation Model (SRM) is an affordable, easy, and non-pharmacological way that clinics can use to cope with dysmenorrhoea.
METHOD: This study aimed to investigate how psychoeducation affected dysmenorrhoea for nursing students using SRM. The sample consisted of 66 female students suffering from moderate-to-severe menstrual pain. A three-session psychoeducation based on SRM was applied to the intervention group. An 'Introductory Information Form', 'Visual Analogue Scale', 'Functional and Emotional Measure of Dysmenorrhoea (FEMD)', and 'Menstrual Symptom Questionnaire (MSQ)' were used to collect the data. All the measurements were carried out over three consecutive menstrual cycles.
RESULTS: A generalised linear model was used to analyse the data. After receiving psychoeducation, the pain and functional and emotional symptoms of dysmenorrhoea mean scores significantly decreased in the intervention group compared to the control group (p < .05), whereas there was no significant difference between the groups' MSQ mean scores (p > .05).
CONCLUSION: The psychoeducation reduced the severity of dysmenorrhoea pain and the functional and emotional impact levels of dysmenorrhoea and it was proved to be effective at helping the subjects cope with pain in the long term.
This invention relates generally to apparatus and processes for preparing fibrinogen glue from autologus plasma. More particularly, this invention relates to a novel apparatus comprising a plasma memberane separator to extract and separate the autologus plasma from other undesirable compositions in the blood. The autologous plasma is transferred to a membrane separator to provide separation of the fibrinogen from other compositions with a desirable amount of ether or other suitable solvents containing an -OH group in the presence of a mixing means. The fibrinogen so separated is transferred to a fibrinogen collector which is connected to a vacuum pump through a sterile filter to remove the ether or other suitable solvents contained thereof. A freezer is provided to maintain the autologus plasma in the membrane separator and the fibrinogen in the fibrinogen collector at a desirable temperature. Additionally, a constant temperature bisyringe serves to keep the fibrinogen liquid and mixed with thrombin to form a homogeneous clotting to achieve hemostasis and tissue approximation. A second embodiment which provides a method of producing fibrin glue without the need of ether or organic solvent is also disclosed.
The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
Because of its life-threatening side effects and the substantial management difficulties associated with amiodarone use (see "WARNINGS" below), Pacerone® (Amiodarone HCl) Tablets are indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated.

  1. Recurrent ventricular fibrillation.
  2. Recurrent hemodynamically unstable ventricular tachycardia.



As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone HCl tablets favorably affects survival.

Pacerone® (Amiodarone HCl) Tablets should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. Because of the life-threatening nature of the arrhythmias treated, potential interactions with prior therapy and potential exacerbation of the arrhythmia, initiation of therapy with Pacerone® (Amiodarone HCl) Tablets should be carried out in the hospital.